Chronic hepatitis C and no response to antiviral therapy:A perpetual problem

 
Το τεκμήριο παρέχεται από τον φορέα :

Αποθετήριο :
Annals of Gastroenterology
δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
κοινοποιήστε το τεκμήριο




2007 (EL)
Chronic hepatitis C and no response to antiviral therapy:A perpetual problem (EN)

Cholongitas, E.
Papatheodoridis G.,

SUMMARY No-response to antiviral therapy was observed in the majority of chronic hepatitis C patients treated with interferon alpha (IFN-a) monotherapy, but continues to represent a frequent problem even after treatment with newer, more potent, combination regimens. Non-responding patients represent a fairly heterogeneous group. Subgroups of nonresponders with biochemical but without virological response, or with breakthrough phenomena during therapy probably have a relatively more favorable prognosis. Retreatment with consensus IFN may be relatively effective, while the combination of IFN-a in usual dosage and ribavirin (RIB) achieves sustained virological response in 13% and 21% of such patients treated for 6 and 12 months, respectively. Induction courses of IFN-a in combination with RIB have been found to achieve initial virological response in 36-40% and sustained virological response in 17-26%. Triple antiviral therapy with IFN-a, RIB and amantadine has also been used, but more trials are needed for firm conclusions. Recently, the combination of pegylated IFN-a plus ribavirin was reported to achieve initial virological response in 36-40% of patients non-responding to IFN-a monotherapy or to a combination of IFN-a plus ribavirin. Extensive data suggest that therapy with IFN-a may delay the progression of fibrosis and decrease the incidence of hepatocellular carcinoma even in non-responding chronic hepatitis C patients. Thus, the decision whether or not to discon-tinue the antiviral therapy in non-responders is related to whether therapy aims the clearance of the virus or just a histological benefit. Key words: Chronic hepatitis C, no-response, Interferon, Ribavirin, Amantadine, Induction therapy (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Society of Gastroenterology (EN)

2007-03-19


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 15, No 2 (2002) (EN)



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.